Absorption and presystemic metabolism
The pharmacokinetic profile of metoprolol is based on its chemical nature—it is a distinctly lipophilic compound. Due to its high solubility in fats, the drug demonstrates an excellent degree of absorption in the gastrointestinal tract: after oral administration, more than 90% of the active substance is absorbed from the intestine.
However, a high absorption rate does not correlate with the final drug concentration in the blood. The systemic bioavailability of metoprolol remains at a paradoxically low level, ranging from only 40 to 50 percent. The reason for this pharmacokinetic phenomenon is intensive presystemic metabolism in hepatocytes. In clinical pharmacology, this process is also referred to as the hepatic "first-pass effect." Upon entering the portal venous system, a significant portion of the molecules undergoes immediate enzymatic transformation without ever reaching the systemic circulation.
Genetic polymorphism and CYP2D6
The key enzyme responsible for the biotransformation of metoprolol in the body is the CYP2D6 cytochrome system isoenzyme. A major clinical challenge is the pronounced genetic polymorphism of this enzyme in the human population. The rate of drug cleavage and elimination is a strictly individual parameter.
Depending on the genetic profile, the half-life ($T_{1/2}$) can vary within a very wide range—from the standard 3 hours to a prolonged 7–8 hours. Special attention is required when prescribing therapy to so-called "poor metabolizers." In such patients, an abnormally low activity of hepatic enzyme systems is genetically determined. As a result, the plasma concentration of the drug rises rapidly, and the risk of severe side effects increases approximately 5-fold compared to individuals with a normal metabolic phenotype.
Mechanism of action: pharmacodynamic nuances
From the perspective of its cellular-level mechanism of action, metoprolol has one crucial feature that distinguishes it from simple blockers. The drug acts as an inverse agonist.
This means that the molecule does not merely competitively shield the receptor from the effects of endogenous catecholamines (adrenaline and noradrenaline). Metoprolol is capable of actively suppressing the spontaneous, or basal, activity of $\beta$-adrenoreceptors. Even in the complete absence of a stimulating ligand, receptors can maintain a background level of activation, and it is precisely this unique ability of metoprolol to abolish this basal level that ensures its consistently high therapeutic efficacy.
Practical aspects of application
Indications for prescribing this agent are generally similar to those for propranolol. Medical practice provides two main routes of administration:
- Intravenously — for the rapid management of acute conditions.
- Orally (per os) — for long-term maintenance therapy. It is recommended to take the drug with food, and the frequency of administration is usually 2–3 times a day.
A specific approach is required when treating patients with chronic heart failure (CHF). In such clinical situations, the use of standard immediate-release formulations is irrational and can be hazardous. Therefore, exclusively specialized prolonged-action drugs (e.g., Betaloc ZOK or Egilok Retard) are used in CHF. They maintain a stable therapeutic concentration of the active substance by smoothing out peaks and troughs, which is vital for the exhausted myocardium.
Briefly: answers to topical questions
What is the selectivity class of metoprolol?
Metoprolol belongs to cardioselective drugs, which are selective $\beta_1$-receptor blockers. The cardioselectivity index for metoprolol is 25/1, reflecting a moderate degree of selectivity.
- Cardioselective (selective $\beta_1$-receptor blockers) — drugs that predominantly block $\beta_1$-adrenoreceptors in the heart with lesser effects on $\beta_2$-receptors.
What are the main clinical indications for prescribing metoprolol?
Metoprolol is used for various cardiovascular pathologies. The main indications are arterial hypertension, angina pectoris, and coronary artery disease, as well as acute myocardial infarction and acute coronary syndrome as the drug of choice for intravenous administration.
- Arterial hypertension (hypertensio arterialis) — elevated blood pressure.
- Angina pectoris (angina pectoris) — coronary artery disease accompanied by pain attacks.
- Myocardial infarction (infarctus myocardii) — the acute period for ischemia control and prevention of ventricular arrhythmias.
What are the absolute contraindications to the use of metoprolol?
Contraindications to the use of metoprolol include:
- Sinoatrial block grade II–III.
- Atrioventricular block grade II–III.
- Sinus bradycardia in the absence of an implanted pacemaker.
- Arterial hypotension.
- Chronic heart failure functional class IV.
- Bronchial obstruction syndrome.
Class and exam questions
Why is the drug's bioavailability no higher than 50% despite almost complete intestinal absorption?
Absorption exceeds 90%, but due to high lipophilicity, metoprolol is actively taken up by liver enzymes. This presystemic metabolism (first-pass effect) eliminates more than half of the administered dose before it reaches the systemic circulation.
What is the primary danger of prescribing the drug to "poor metabolizers"?
In such patients, the activity of the CYP2D6 enzyme is genetically reduced. The half-life increases to 7–8 hours, the drug begins to accumulate in the body, and the risk of adverse side effects increases 5-fold.
What does the term "inverse agonist" mean in the context of the mechanism of action?
This property means that the drug not only mechanically blocks mediator access to the receptor but also actively suppresses its intrinsic spontaneous (basal) activity, providing a more pronounced clinical effect.
Which pharmaceutical formulations of metoprolol are indicated for chronic heart failure?
In the treatment of CHF, only prolonged-action drugs (e.g., Betaloc ZOK) are used, which ensure gradual release of the substance and prevent sharp fluctuations in blood concentration.
What else to study on this topic
- Genetic polymorphism of cytochrome P450 enzymes and personalized medicine.
- Pharmacodynamics of inverse agonists: differences from classical antagonists.
- Comparison of the pharmacokinetics of lipophilic and hydrophilic beta-blockers.
- First-pass hepatic effect: mechanisms and clinical significance.
- Comparative characteristics of metoprolol and propranolol.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Metoprolol" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs Acting on Adrenergic Synapses"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.